An Openlabel, expanded acess protocol for Amifampridine Phosphate (3.4Diaminopyridine Phosphate) treatment in patients with LambertEaton Myasthenic Syndrome (LEMS), congenital myasthenic syndrome and downbeat nystagmus.

Project: Other project

StatusFinished
Effective start/end date2/24/162/23/18

Funding

  • Catalyst Pharmaceuticals Inc: $5,384.62